Home / Prices / Intravitreal injection of conbercept

Intravitreal injection of conbercept

Eye Care estimated about CNY 3500-4500

Disclaimer: This site is a medical service platform; some page content is AI-assisted. Health-related information does not constitute medical advice. If you have any questions, please consult a healthcare professional. See full disclaimer

Description

A procedure involving the administration of conbercept, a recombinant fusion protein that inhibits vascular endothelial growth factor (VEGF), directly into the vitreous cavity to treat retinal vascular diseases.

Main Uses

Primary clinical use is intravitreal treatment of neovascular (wet) age-related macular degeneration (nAMD), myopic choroidal neovascularization (mCNV), and diabetic macular edema (DME). It inhibits vascular endothelial growth factor (VEGF)-A, VEGF-B, and placental growth factor (PlGF), thereby reducing abnormal blood vessel growth, vascular leakage, and retinal edema. Administered as an off-label or approved (in China) therapy based on disease activity, anatomical response (OCT), and functional outcomes (visual acuity).

Normal Range

Not applicable — anti-VEGF intravitreal injection (Conbercept) is a therapeutic procedure, not a diagnostic laboratory test with quantitative biomarker values. There is no 'normal range' for the injection itself; efficacy and safety are assessed clinically via OCT, visual acuity, fundus imaging, and intraocular pressure monitoring.

Low Values - Possible Causes

N/A — 'Low value' is not meaningful for this intervention, as Conbercept is not a measurable circulating biomarker. However, suboptimal clinical response (e.g., persistent fluid or vision loss) may result from inadequate dosing frequency, poor drug penetration, tachyphylaxis, non-VEGF-driven pathology (e.g., inflammatory or fibrotic components), or patient-specific pharmacokinetic variability.

High Values - Possible Causes

N/A — 'High value' does not apply, as Conbercept administration is not quantified in systemic or ocular fluid concentrations post-injection for routine clinical decision-making. Excessive dosing may increase risks (e.g., intraocular inflammation, RPE atrophy, geographic atrophy, or sustained IOP elevation), but these are adverse events—not 'high values' of a test.

anti-VEGF therapy intravitreal injection Conbercept

estimated about CNY 3500-4500